MetaVia Inc. (MTVA)
NASDAQ: MTVA · Real-Time Price · USD
8.63
-0.37 (-4.11%)
At close: Dec 30, 2025, 4:00 PM EST
8.50
-0.13 (-1.51%)
After-hours: Dec 30, 2025, 7:11 PM EST
MetaVia Employees
MetaVia had 9 employees as of December 31, 2024. The number of employees increased by 1 or 12.50% compared to the previous year.
Employees
9
Change (1Y)
1
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$1,801,778
Market Cap
19.00M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9 | 1 | 12.50% |
| Dec 31, 2023 | 8 | 6 | 300.00% |
| Dec 31, 2022 | 2 | -3 | -60.00% |
| Dec 31, 2021 | 5 | -2 | -28.57% |
| Dec 31, 2020 | 7 | -5 | -41.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MTVA News
- 1 day ago - MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference - PRNewsWire
- 8 days ago - MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement - PRNewsWire
- 4 weeks ago - MetaVia Inc. Announces 1-for-11 Reverse Stock Split - PRNewsWire
- 7 weeks ago - MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025 - PRNewsWire
- 7 weeks ago - MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025 - PRNewsWire
- 2 months ago - MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting - PRNewsWire
- 2 months ago - MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025 - PRNewsWire